Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Toxicity From CD19, BCMA Therapy May Inform B-Cell Malignancy Surveillance
2
Nogapendekin Alfa Plus BCG Exhibits Efficacy Advantage in NMIBC In Situ
3
Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols
4
Fianlimab Combo Does Not Significantly Improve PFS in Advanced Melanoma
5